1259391-06-4Relevant articles and documents
Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility
Ohashi, Masao,Oyama, Takuji,Putranto, Endy Widya,Waku, Tsuyoshi,Nobusada, Hiromi,Kataoka, Ken,Matsuno, Kenji,Yashiro, Masakazu,Morikawa, Kosuke,Huh, Nam-Ho,Miyachi, Hiroyuki
, p. 2319 - 2332 (2013/05/09)
In the continuing study directed toward the development of peroxisome proliferator-activated receptor gamma (hPPARγ) agonist, we attempted to improve the water solubility of our previously developed hPPARγ-selective agonist 3, which is insufficiently soluble for practical use, by employing two strategies: introducing substituents to reduce its molecular planarity and decreasing its hydrophobicity via replacement of the adamantyl group with a heteroaromatic ring. The first approach proved ineffective, but the second was productive. Here, we report the design and synthesis of a series of α-benzyl phenylpropanoic acid-type hPPARγ partial agonists with improved aqueous solubility. Among them, we selected (R)-7j, which activates hPPARγ to the extent of about 65% of the maximum observed with a full agonist, for further evaluation. The ligand-binding mode and the reason for the partial-agonistic activity are discussed based on X-ray-determined structure of the complex of hPPARγ ligand-binding domain (LBD) and (R)-7j with previously reported ligand-LDB structures. Preliminal apoptotic effect of (R)-7j against human scirrhous gastric cancer cell line OCUM-2MD3 is also described.
Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: Discovery of reversed stereochemistry-activity relationship
Ohashi, Masao,Oyama, Takuji,Nakagome, Izumi,Satoh, Mayumi,Nishio, Yoshino,Nobusada, Hiromi,Hirono, Shuichi,Morikawa, Kosuke,Hashimoto, Yuichi,Miyachi, Hiroyuki
, p. 331 - 341 (2011/03/22)
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-mediated transcription factor with roles in glucose, lipid, and lipoprotein homeostasis, and PPARγ ligands are expected have therapeutic potential in these as well as other areas. We rep